Chau Q. Khuong is a biotech entrepreneur and venture capital investor. He is currently a venture partner at OrbiMed Advisors, a global healthcare-dedicated investment firm with over $15 billion in assets under management. Over the past two decades, he has been an active lead investor in innovative drug development and medical device enterprises across all stages and therapeutic areas including oncology, infectious diseases, ophthalmology, gene therapy and gene editing.

Mr. Khuong has served in a board capacity of numerous public and private companies, including Arius Research (acquired by Roche), Durata (acquired by Actavis), Fusion Pharmaceuticals (NASDAQ: FUSN), Glaukos Medical (NYSE: GKOS), Intellia Pharmaceuticals (NASDAQ: NTLA), Intercept Pharmaceuticals (NASDAQ: ICPT), Inspire Medical Systems (NYSE: INSP), NextCure (NASDAQ: NXTC), Pieris (NASDAQ: PIRS) and Rempex (acquired by Medicines Company). He holds a BS in molecular, cellular and developmental biology with a concentration in biotechnology and an MPH with a concentration in infectious diseases, both from Yale University.